Active clinical trials for "Anemia, Iron-Deficiency"

Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

In this study intermittent dosage of iron supplementation three times a week will be compared to daily dosage in anaemic pregnant women due to iron deficiency.

The goal of this clinical trial is to determine if taking a mineral-enriched powder can raise blood iron levels compared to a placebo powder in reproductive-aged women with iron deficiency. The main questions it aims to answer are: Does the mineral-enriched powder raise blood iron levels compared to a placebo powder in women when it is taken every day for six months? How many participants still have iron deficiency after six months of taking the mineral-enriched powder compared to a placebo powder? Participants in this clinical trial will drink the mineral-enriched powder containing ferrous iron and zinc sulphate monohydrate or a placebo powder mixed with 1 litre of water daily for six months. The placebo is a look-alike substance that does not contain active ingredients (iron and zinc). Participants will also have to: Complete an online "study diary" every two weeks for six months Provide a blood sample once a month for six months Attend three in-person visits with a researcher, at enrolment (baseline), midline (three months), and endline (six months) Complete three sets of online questionnaires (following each in-person visit) Complete three sets of dietary assessments (following each in-person visit) Provide three stool samples (following each in-person visit)

This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.

Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion. The goal of this clinical trial: Correct IDA with fewer visits and less impact on the healthcare system Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.

Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle- income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given at time of vaccination improved response to yellow fever and Coronavirus disease 2019 (COVID-19) vaccines in IDA Kenyan women. Whether oral iron treatment would have a similar beneficial effect on vaccine response is uncertain. Also, timing of oral iron treatment needs further investigation. The co-primary objectives of this study are to assess 1) whether IDA in Kenyan women impairs vaccine response, and whether oral iron treatment improves the participants' response; 2) the timing of oral iron treatment to improve vaccine response (prior to vaccination vs at time of vaccination). The investigators will conduct a double-blind randomized controlled trial in southern Kenya to assess the effects of iron supplementation on response to two single-shot vaccines: Johnson & Johnson COVID- 19 (JJ COVID-19) and the quadrivalent meningococcal vaccine (MenACWY). Women with IDA will be recruited and randomly assigned to three study groups: group 1 (pre- treatment) will receive 200 mg oral iron as ferrous sulfate (FeSO4) on alternate days on days 1-56; group 2 (simultaneous treatment) will receive matching placebo on alternate days on days 1-28, and 200 mg oral iron as FeSO4 on alternate days on days 29-56; and group 3 (control) will receive matching placebo on alternate days on days 1-56. Women in all groups will receive the JJ COVID-19 vaccine and the MenACWY vaccine on day 28. Cellular immune response will be measured at 7 days after vaccination and serology will be measured at 28 days after vaccination in all groups.

The objective is to investigate the treatment of non-anemic iron deficiency (NAID) and the impact on development of anemia later in pregnancy. Anemia in the third trimester has been identified as a risk factor for maternal and fetal morbidity that might lead to mortality. Due to the high incidence of NAID in pregnancy, there is an opportunity for early screening and treatment to decrease progression to anemia. The primary aim of this study is to establish if treatment of NAID will result in higher third trimester hemoglobin values and decrease incidence of anemia at term.

This study was designed to investigate the effect of iron sucrose combined with rHuEPO and ascorbic acid on perioperative allogeneic red blood cell transfusion in patients undergoing elective major cardiac surgery by evaluating outcome indicators such as perioperative allogeneic red blood cell transfusion rates and changes in perioperative haemoglobin levels.

Obesity and iron deficiency (ID) are two forms of the most usual nutritional disorders worldwide. Iron deficiency remains the most common nutritional deficiency and cause of anemia worldwide. Populations in the developing countries, premenopausal females, pregnant women, children, vegetarians and frequent blood donors are largely affected by iron deficiency due to low dietary intake, inadequate bioavailable iron, increased iron demand required for growth and development, iron losses and changes in blood volume. WHO recognized obesity as disease, which is prevalent in both developing and developed countries. Overweight and obesity are now so common and thereby replacing the more traditional public health concerns (under nutrition and infectious diseases) as some of most significant contributors to ill health. The aim of this study is to investigate effect of aerobic exercise and diet on obese anemic premenopausal women which not clarified previously. It will be hypothesized that: There will be no significant effect of aerobic exercise and diet on the anthropometric and hematological measurements in obese anemic women.

The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.